ISMRC 2023 Final Programme

27 PS-03-021 Development of a target-capture NGS assay for use in molecular-based re- search of myeloid Measurable Residual Disease Rebecca Biloune, United Kingdom PS-03-022 Noninvasive, dynamic risk profiling of aggressive B-cell lymphomas by peri- pheral blood circulating tumor DNA sequencing Sven Borchmann, Germany PS-03-023 Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients Karin Birkenkamp-Demtröder, Denmark PS-03-024 ctDNA BRCA1-methylation can predict therapy efficacy in ovarian and breast cancer patients Simon Joosse, Germany Tuesday, 2 May 2023 – Poster Sessions AUTOMATE THE IMAGING, DETECTION & CHARACTERIZATION OF YOUR CTC ASSAY Exclusive Features: • Compatible with any cell enrichment & biomarker combination • Innovative AI Deep Learning CTC detection algorithms • Automated cellular features extraction • Web app for easy sharing and collaboration